Johnson & Johnson (NYSE:JNJ - Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Traders bought 40,778 call options on the company. This represents an increase of approximately 45% compared to the typical daily volume of 28,147 call options.
Analyst Ratings Changes
A number of equities research analysts have recently commented on the stock. Guggenheim increased their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a report on Wednesday, November 6th. Citigroup lowered their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an "outperform" rating and a $190.00 price objective on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Royal Bank of Canada increased their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an "outperform" rating in a research report on Wednesday, October 16th. Eight investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $173.27.
Read Our Latest Research Report on JNJ
Insider Activity
In other news, Director Mark A. Weinberger purchased 1,000 shares of the business's stock in a transaction dated Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company's stock.
Institutional Trading of Johnson & Johnson
A number of hedge funds and other institutional investors have recently modified their holdings of JNJ. Itau Unibanco Holding S.A. grew its stake in Johnson & Johnson by 7.5% during the second quarter. Itau Unibanco Holding S.A. now owns 3,018 shares of the company's stock valued at $441,000 after acquiring an additional 211 shares in the last quarter. Harmony Asset Management LLC grew its stake in Johnson & Johnson by 22.2% during the second quarter. Harmony Asset Management LLC now owns 19,211 shares of the company's stock valued at $2,808,000 after acquiring an additional 3,490 shares in the last quarter. Magnetar Financial LLC purchased a new position in Johnson & Johnson during the second quarter valued at $80,751,000. Evergreen Capital Management LLC grew its stake in Johnson & Johnson by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 110,063 shares of the company's stock valued at $16,087,000 after acquiring an additional 4,009 shares in the last quarter. Finally, Providence Capital Advisors LLC grew its stake in shares of Johnson & Johnson by 12.4% in the 2nd quarter. Providence Capital Advisors LLC now owns 40,909 shares of the company's stock worth $5,979,000 after buying an additional 4,500 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Price Performance
Shares of NYSE JNJ traded up $1.07 during midday trading on Tuesday, reaching $148.10. The stock had a trading volume of 11,094,063 shares, compared to its average volume of 8,798,511. The stock has a 50-day moving average of $148.35 and a 200-day moving average of $156.11. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company has a market capitalization of $356.57 billion, a price-to-earnings ratio of 21.43, a price-to-earnings-growth ratio of 2.39 and a beta of 0.51. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.35%. Johnson & Johnson's dividend payout ratio (DPR) is presently 71.78%.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
